Oropharyngeal Cancers Recruiting Phase 2 Trials for Nimotuzumab (DB06192)

Also known as: Oropharyngeal Cancer / Cancer of Oropharnyx

IndicationStatusPhase
DBCOND0042409 (Oropharyngeal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01516996Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx CancerTreatment